Works matching Paclitaxel

Results: 5000
    1
    2
    3
    4
    5
    6
    7
    8
    9
    10
    11
    12
    13

    Nanoparticle albumin-bound paclitaxel and ramucirumab versus paclitaxel and ramucirumab as second-line chemotherapy for unresectable advanced or recurrent gastric cancer: a multicenter, propensity score-matched analysis (CROSS SELL study).

    Published in:
    International Journal of Clinical Oncology, 2022, v. 27, n. 4, p. 684, doi. 10.1007/s10147-022-02114-y
    By:
    • Nakasya, Akio;
    • Hagiwara, Yuya;
    • Ikoma, Tatsuki;
    • Kurioka, Yusuke;
    • Matsumoto, Toshihiko;
    • Yamamoto, Yoshiyuki;
    • Tsuduki, Takao;
    • Kajiwara, Takeshi;
    • Moriwaki, Toshikazu;
    • Nishina, Tomohiro;
    • Yamashita, Natsumi;
    • Hyodo, Ichinosuke
    Publication type:
    Article
    14
    15
    16
    17
    18
    19

    Clinical consequences of the Calypso trial showing superiority of PEG-liposomal doxorubicin and carboplatin over paclitaxel and carboplatin in recurrent ovarian cancer: Results of an Austrian gynecologic oncologists' expert meeting.

    Published in:
    Wiener Klinische Wochenschrift, 2010, v. 122, n. 21/22, p. 649, doi. 10.1007/s00508-010-1483-1
    By:
    • Petru, Edgar;
    • Reinthaller, Alexander;
    • Angleitner-Boubenizek, Lukas;
    • Schauer, Christian;
    • Zeimet, Alain;
    • Dirschlmayer, Wolfgang;
    • Medl, Michael;
    • Stummvoll, Wolfgang;
    • Sevelda, Paul;
    • Marth, Christian
    Publication type:
    Article
    20
    21
    22
    23
    24
    25
    26
    27

    A Pilot, Phase II, Randomized, Open‐Label Clinical Trial Comparing the Neurotoxicity of Three Dose Regimens of Nab‐Paclitaxel to That of Solvent‐Based Paclitaxel as the First‐Line Treatment for Patients with Human Epidermal Growth Factor Receptor Type 2‐Negative Metastatic Breast Cancer

    Published in:
    Oncologist, 2019, v. 24, n. 11, p. e1024, doi. 10.1634/theoncologist.2017-0664
    By:
    • Ciruelos, Eva;
    • Apellániz‐Ruiz, María;
    • Cantos, Blanca;
    • Martinez‐Jáñez, Noelia;
    • Bueno‐Muiño, Coralia;
    • Echarri, Maria‐Jose;
    • Enrech, Santos;
    • Guerra, Juan‐Antonio;
    • Manso, Luis;
    • Pascual, Tomas;
    • Dominguez, Cristina;
    • Gonzalo, Juan‐Francisco;
    • Sanz, Juan‐Luis;
    • Rodriguez‐Antona, Cristina;
    • Sepúlveda, Juan‐Manuel
    Publication type:
    Article
    28
    29
    30
    31
    32

    A phase I/randomized phase II, non-comparative, multicenter, open label trial of CP-547,632 in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC).

    Published in:
    Cancer Chemotherapy & Pharmacology, 2007, v. 60, n. 1, p. 81, doi. 10.1007/s00280-006-0352-0
    By:
    • Cohen, Roger B.;
    • Langer, Corey J.;
    • Simon, George Rajan;
    • Eisenberg, Peter David;
    • Hainsworth, John Daniel;
    • Madajewicz, Stefan;
    • Cosgriff, Thomas Michael;
    • Pierce, Kristen;
    • Huiping Xu;
    • Liau, Katherine;
    • Healey, Diane
    Publication type:
    Article
    33
    34
    35
    36
    37
    38
    39
    40
    41
    42
    43
    44
    45
    46
    47
    48
    49

    Phase II multi-institutional prospective randomized trial comparing S-1 plus paclitaxel with paclitaxel alone as second-line chemotherapy in S-1 pretreated gastric cancer (CCOG0701).

    Published in:
    International Journal of Clinical Oncology, 2016, v. 21, n. 3, p. 557, doi. 10.1007/s10147-015-0919-z
    By:
    • Nakanishi, Koki;
    • Kobayashi, Daisuke;
    • Mochizuki, Yoshinari;
    • Ishigure, Kiyoshi;
    • Ito, Seiji;
    • Kojima, Hiroshi;
    • Ishiyama, Akiharu;
    • Fujitake, Shinichi;
    • Shikano, Toshio;
    • Morita, Satoshi;
    • Kodera, Yasuhiro
    Publication type:
    Article
    50